Donald Drakeman, the chief executive of New Jersey biotech company Medarex Inc., resigned on Monday, done in by backdated executive stock options that have sparked a shareholders suit, a grand jury subpoena and an SEC investigation. Medarex joins a growing list of businesses, including McAfee Inc. and Monster Worldwide Inc., where a CEO has stepped down in the wake of stock option-related litigation and regulatory investigations.
November 08, 2006 at 12:00 AM
1 minute read
The original version of this story was published on Law.Com
The chief executive of New Jersey’s fourth-largest biotech company resigned on Monday, done in by backdated executive stock options that have sparked a shareholders suit, a grand jury subpoena and a Securities and Exchange Commission investigation.
Medarex Inc., of Princeton, N.J., joins a growing list of businesses, including McAfee Inc. and Monster Worldwide Inc., where a CEO has stepped down in the wake of stock-option-related litigation and regulatory investigations.
Deal Watch: Skadden, Sidley, Slaughter and S&C Lead Big Paper Deal, While Private Funds Grow Massive
Presented by BigVoodoo
Law firms & in-house legal departments with a presence in the middle east celebrate outstanding achievement within the profession.
The premier educational and networking event for employee benefits brokers and agents.
The Legal Intelligencer honors lawyers leaving a mark on the legal community in Pennsylvania and Delaware.
A large and well-established Tampa company is seeking a contracts administrator to support the company's in-house attorney and manage a wide...
We are seeking an attorney to join our commercial finance practice in either our Stamford, Hartford or New Haven offices. Candidates should ...
We are seeking an attorney to join our corporate and transactional practice. Candidates should have a minimum of 8 years of general corporat...
MELICK & PORTER, LLP PROMOTES CONNECTICUT PARTNERS HOLLY ROGERS, STEVEN BANKS, and ALEXANDER AHRENS
